A kind of pharmaceutical compound and its preparation and application

A technology of compounds and uses, applied in the field of pharmaceutical compounds and their preparation and uses, can solve the problems of hydrolysis, absorption, lowering of TXA2/PGI2 ratio, gastrointestinal mucosal damage and other problems in the real sense, so as to avoid gastrointestinal bleeding , reduce the resistance effect, the effect of drug safety

Active Publication Date: 2019-07-23
SHANGHAI HUAIFENG BIOTECHNOLOGY CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, aspirin can also damage the intestinal mucosal barrier, eventually leading to ulcers
(2) Biological toxicity: after absorption, aspirin inhibits cyclooxygenases when passing through the gastrointestinal tract during the distribution and absorption process of the whole body, weakens their protective effect, and leads to the reduction of the production of prostaglandins (prostaglandins) that regulate gastric acid secretion and blood flow, Injury to the mucous membrane of the digestive tract
[0014] It can be seen that the current aspirin drugs have the following problems: low efficiency, low safety, short-acting, poor stability
[0026] Although the formation of aspirin and flavone esters as prodrugs faces great challenges, natural flavone products can improve platelet function, adjust the balance of PGI2 and TXA2, increase PGI2 levels, reduce the ratio of TXA2 / PGI2, inhibit platelet aggregation, and promote damaged blood vessels. Restoring endothelial function, forming aspirin and flavonoids to achieve synergistic antithrombotic effect is still very attractive for clinical research and development, but so far, there is no real hydrolysis, absorption, and metabolism in the body that meet the requirements of antiplatelet therapy. Aggregation Design Requires Aspirin Ester Drug Study Success

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical compound and its preparation and application
  • A kind of pharmaceutical compound and its preparation and application
  • A kind of pharmaceutical compound and its preparation and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0154] Example 1: Preparation of 3-O-((2-acetoxy)-benzoyl)-3',4',7-tri(-O-hydroxyethyl)quercetin

[0155] 1) Troxerutin (10g=10.9mmol, troxerutin chromatographic purity 85%, content 81%) was dissolved in 380ml of water, then added 20ml of concentrated sulfuric acid, heated to reflux for 3 hours, stopped the reaction and cooled down, and cooled to After filtering at room temperature, and then washing with water until neutral, the filter cake was obtained, and vacuum-dried at 65°C to obtain 5.66 g of 3′,4′,7-tris(-O-hydroxyethyl)quercetin with a chromatographic purity of 90.2%. Yield 56.6%.

[0156] 2) In a 100ml three-necked reaction flask, anhydrous 3′,4′,7-tris(-O-hydroxyethyl)quercetin (2g=4.6mmol, water content less than 0.1%) was stirred and dissolved at room temperature in In DMF (40ml), add aspirin (1.66g=9.2mmol) again, then add DCC (1.9g=9.2mmol) and 10% DMAP therein, stir reaction at -5~5 ℃, after 12 hours, reaction finishes, The reaction solution was filtered, and ...

Embodiment 2

[0159] Example 2: Preparation of 3-O-((2-acetoxy)-benzoyl)-3',4',7-tri(-O-hydroxyethyl)quercetin

[0160] (1) Troxerutin (100g=119.9mmol, troxerutin chromatographic purity 92%, content 89%) was dissolved in 3800ml water, then added 200ml concentrated sulfuric acid, heated to reflux for 3 hours, stopped the reaction, and kept warm for 90 Filtrate above ℃, wash with hot water until neutral to obtain a filter cake, and dry it in vacuum at 65℃ to obtain 55.4g of 3′,4′,7-tris(-O-hydroxyethyl)quercetin with a chromatographic purity of 93.8%. Yield 55.4%.

[0161] (2) In a 500ml glass reaction vial, dissolve 10g (23.0mmol) of 3′,4′,7-tris(-O-hydroxyethyl)quercetin obtained in (1) in DMF (200ml) for later use, Add 12.4g (68.9mmol) of aspirin, add 12g of DCC and 12% DMAP to it, stir the reaction at -5~-15°C, after 18 hours, the reaction is completed, the reaction solution is filtered, and the filtrate is added with 15 times saturated ice salt water, stirred, and precipitated The soli...

Embodiment 3

[0163] Example 3: Preparation of 3-O-((2-acetoxy)-benzoyl)-3',4',7-tri(-O-hydroxyethyl)quercetin

[0164] (1) Troxerutin (100g=121.3mmol, troxerutin chromatographic purity 93%, content 90%) was dissolved in 3800ml water, then added 200ml concentrated sulfuric acid, heated to reflux for 3 hours, stopped the reaction, and kept warm for 80 Filtrate above ℃, then wash with hot water until neutral to obtain a filter cake, add 4500ml of ethanol-water (40:60) mixed solvent to the filter cake, stir and heat to reflux for 30 minutes, heat filter, and vacuum-dry the filter cake at 65 °C to obtain 3' , 4', 7-tris(-O-hydroxyethyl) quercetin 53.1g, chromatographic purity 95.1%, yield 53.1%.

[0165] (2) In a 500ml glass reaction vial, dissolve 10g (23.0mmol) of 3′,4′,7-tris(-O-hydroxyethyl)quercetin obtained in (1) in DMF (200ml) for later use, Add 8.3g (46.1mmol) of aspirin, then add 15g of DCC and 15% DMAP to it, and stir the reaction at -15~-25°C. After 26 hours, the reaction is comple...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a drug compound, preparation therefor, and an application thereof. The drug has the structure as represented by formula I after being modified by a flavonol structure. Compared with current anticoagulant drugs, the present invention has the characteristics of high efficiency, low toxicity, long-acting, and stability; the drug has excellent physical and chemical stability, and has excellent stability to water, acid, and alkali.

Description

technical field [0001] The invention relates to a medicine, in particular to a medicine compound and its preparation and application. Background technique [0002] Cardiovascular disease is the first killer of human beings. In 2016, the number of deaths from cardiovascular diseases in the world was 17.65 million, far exceeding the number of tumors (various tumors) (8.93 million). In China, the death toll of ischemic heart disease (coronary heart disease) and ischemic stroke is much higher than the death toll of all cancers, and the situation in the United States is similar. Although the clinical effect of antiplatelet drugs is positive, bleeding side effects are the biggest problem of existing antiplatelet drugs. Existing antiplatelet drugs all have different degrees of bleeding side effects. On the one hand, severe bleeding side effects (such as intracranial hemorrhage) can be fatal and more harmful than the blood clot itself. On the other hand, bleeding side effects lim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D311/30A61K31/625A61P29/00A61P37/02A61P27/16A61P1/16A61P27/12A61P15/00A61P15/04A61P25/28A61P35/00A61P9/00A61P9/10A61P25/00A61P7/02A61P39/06A61P9/12A61P3/06A61P31/04A61P31/10A61P31/12A61P37/08A61P7/10A61P19/10
CPCA61P1/16A61P3/06A61P7/02A61P7/10A61P9/00A61P9/10A61P9/12A61P15/00A61P15/04A61P19/10A61P25/00A61P25/28A61P27/12A61P27/16A61P29/00A61P31/04A61P31/10A61P31/12A61P35/00A61P37/02A61P37/08A61P39/06C07D311/30
Inventor 李大鹏
Owner SHANGHAI HUAIFENG BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap